NASDAQ$AVXL
Anavex Life Sciences Corp · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
AVXL reported Q1 2026, net loss of $5.7M, diluted EPS of $-0.06.
For Q1 2026, AVXL reported a net loss of $5.7M, diluted EPS was $-0.06. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Net loss $5.7M.
- Diluted EPS $-0.06.
- AVXL MD&A covers liquidity, operations, and outlook.
Headline financials
Revenue & EPS history
Anavex · Revenue · Quarterly
$1.12M
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks; numeric multi-quarter bridges vary by issuer.
Tailwinds
- MD&A highlights liquidity, capital, and core business trends.
- Segment or product commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure near-term margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+0.4%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+7.1%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+26.0%
Q4 2024
Best reaction
-24.8%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -5.9% | +8.4% | — | |
| Q1 2026 | +6.1% | -4.1% | +13.4% | |
| Q4 2025 | +12.4% | +24.4% | +20.8% | |
| Q3 2025 | -4.9% | -12.4% | -15.6% | |
| Q2 2025 | -1.3% | +1.2% | +24.2% | |
| Q1 2025 | +4.9% | +2.8% | +13.8% | |
| Q4 2024 | +26.0% | +40.3% | +15.8% | |
| Q3 2024 | -5.7% | -2.2% | -13.8% | |
| Q2 2024 | +2.7% | +16.2% | +4.3% | |
| Q1 2024 | -1.7% | +6.0% | -5.9% | |
| Q4 2023 | -4.1% | +7.1% | +40.2% | |
| Q3 2023 | +22.0% | +14.8% | +0.4% | |
| Q2 2023 | +11.3% | +8.2% | +9.9% | |
| Q1 2023 | -1.6% | -5.1% | -12.9% | |
| Q4 2022 | -24.8% | +1.3% | -31.1% | |
| Q3 2022 | +1.9% | +1.7% | -12.9% | |
| Q2 2022 | -3.7% | +13.2% | +12.5% | |
| Q1 2022 | +13.9% | +9.2% | -1.2% | |
| Q4 2021 | +8.2% | +13.7% | +8.5% | |
| Q3 2021 | +8.6% | +7.4% | +3.9% | |
| Q2 2021 | +7.3% | +10.6% | +50.0% | |
| Q1 2021 | -3.4% | -3.3% | +2.6% | |
| Q4 2020 | -4.2% | -6.1% | +4.9% | |
| Q3 2020 | -7.7% | -13.7% | -16.4% | |
| Q2 2020 | +4.5% | +18.9% | +17.1% | |
| Q1 2020 | +5.6% | +12.4% | +7.9% | |
| Q4 2019 | -2.0% | +0.4% | +23.8% | |
| Q3 2019 | +5.5% | -0.4% | +12.2% | |
| Q2 2019 | -1.3% | -1.3% | -4.2% | |
| Q1 2019 | +13.0% | +19.2% | +36.1% | |
| Q4 2018 | -3.8% | -10.4% | -5.2% | |
| Q3 2018 | -5.5% | -3.8% | -7.6% | |
| Q2 2018 | -0.9% | +4.5% | +70.0% | |
| Q1 2018 | -8.4% | -11.2% | +4.6% | |
| Q4 2017 | -13.3% | -14.6% | -10.3% | |
| Q3 2017 | -6.3% | -10.0% | +22.1% | |
| Q2 2017 | -3.6% | -0.5% | -1.2% | |
| Q1 2017 | +5.7% | +12.2% | +3.1% | |
| Q4 2016 | -2.8% | -6.2% | -6.2% | |
| Q3 2016 | +22.1% | +9.6% | -0.7% | |
| Q2 2016 | -10.9% | — | — | |
| Q1 2016 | -20.0% | — | — | |
| Q4 2015 | -21.8% | — | — | |
| Q3 2015 | +13.9% | — | — | |
| Q2 2015 | -5.3% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +17.6% | — | — | |
| Q3 2014 | +4.2% | — | — | |
| Q2 2014 | -8.3% | — | — | |
| Q1 2014 | -9.7% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +1.4% | — | — | |
| Q2 2013 | +8.2% | — | — | |
| Q1 2013 | +5.6% | — | — | |
| Q4 2012 | -1.3% | — | — | |
| Q3 2012 | -17.6% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +14.4% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q3 2011 | -0.9% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -1.6% | — | — | |
| Q4 2010 | -0.3% | — | — | |
| Q3 2010 | +0.9% | — | — | |
| Q2 2010 | +1.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro